Abstract
Identification of the expression profile of exosomal lncRNAs in plasma from PE patients to provide new insights into the molecular mechanism. Five pregnant patients with early-onset severe PE were included in the PE group and 5 normal pregnant patients were included in the control group in the training cohort. Differential expression of genes were identified between the two groups, and were verified in plasma exosomes from 12 additional pregnant patients with EPE and 12 normal pregnant patients. KEGG pathway analysis and GO enrichment analysis were performed using online prediction databases to construct a lncRNA-miRNA-mRNA co-expression network. From there a panel of candidate lncRNAs was selected and validated via quantitative PCR in the two groups. In the 289 differential lncRNA, 155 were up-regulated and 134 were down-regulated. Bioinformatics enrichment analysis demonstrated that the target genes of differential expression of lncRNAs were enriched in 159 pathways with P < 0.05, including cancer, metabolic and PI3K-Akt signaling pathways. Three lncRNAs exhibited significant differential expressed in exosomes between the two groups. A lncRNA-miRNA-mRNA co-expression network analysis showed that ENST00000559730-hsa-miR-661-NUDT16 was the most frequently associated with susceptibility-relation of PE. The significant differences of plasmatic exosomal lncRNA expression between normal pregnant women and early-onset severe PE patients suggest that lncRNA may participate in the pathogenetic process of PE. Our study provides a preliminary bioinformatic foundation in order to find PE markers in plasma which further increase the sample size, and continue to verify the function of lncRNA in vitro.